Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of γ-melanocyte- stimulating hormone

Experimental Physiology

Volumn 94, Issue 8, 2009, Pages 867-876

  Ni, Xi Ping ^a   Van Dijk, Claudia ^a   Pearce, David ^a   Humphreys, Michael H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; GAMMA INTERMEDIN; GLUCOSE; HYDRALAZINE; NORADRENALIN; PHENTOLAMINE; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG INFUSION; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HIGH SODIUM INTAKE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROLACTIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; TREATMENT DURATION;

EID: 67749113768     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2009.046748     Document Type: Article

References (38)

1. Adams JM, Madden CJ, Sved AF & Stocker SD (2007). Increased dietary salt enhances sympathoexcitatory and sympathoinhibitory responses from the rostral ventrolateral medulla. Hypertension 50, 354 359.
2. Bealer SL & Metcalf CS (2005). Increased dietary sodium enhances activation of neurons in the medullary cardiovascular pathway during acute sodium loading in the rat. Auton Neurosci 117, 33 40.
3. Bogaert YE & Linas S (2009). The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 5, 101 111.
4. Campese VM (1994). Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension 23, 531 550.
5. Carey RM, Van Loon GR, Baines AD & Kaiser DL (1983). Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J Clin Endocrinol Metab 56, 595 602.
6. De Wildt DJ, Van Der Ven JC, Van Bergen P, De Lang H & Versteeg DH (1994). A hypotensive and bradycardic action of γ2-melanocyte-stimulating hormone (γ2-MSH) microinjected into the nucleus tractus solitarii of the rat. Naunyn Schmiedebergs Arch Pharmacol 349, 50 56.
7. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L & Bevilacqua S (1987). Insulin resistance in essential hypertension. N Engl J Med 317, 350 357.
8. Franchi F, Lazzeri C, Barletta G, Ianni L & Mannelli M (2001). Centrally mediated effects of bromocriptine on cardiac sympathovagal balance. Hypertension 38, 123 129.
9. Humphreys MH (2004). γ-MSH, sodium metabolism, and salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 286, R417 R430.
10. Humphreys MH (2007). Cardiovascular and renal actions of melanocyte-stimulating hormone peptides. Curr Opin Nephrol Hypertens 16, 32 38.
11. Ibarra F, Crambert S, Eklof AC, Lundquist A, Hansell P & Holtback U (2005). Prolactin, a natriuretic hormone, interacting with the renal dopamine system. Kidney Int 68, 1700 1707.
12. Isogai O, Tsukamoto K, Masubuchi Y, Tomioka S, Suzuki T, Kawato H, Yajima Y, Kasamaki Y, Ito S & Kanmatsuse K (2005). High salt diet enhances cardiovascular responses from the nucleus tractus solitarius and ventrolateral medulla of Sprague-Dawley rats. Clin Exp Hypertens 27, 33 44.
13. Kanayama Y, Kohno M, Takaori K, Itoh S, Yasunari K & Takeda T (1987). Involvement of sympathetic nervous system inhibition in the hypotensive effect of bromocriptine in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 14, 141 144.
14. Khalil R (2006). Dietary salt and hypertension: new molecular targets add more spice. Am J Physiol Regul Integr Comp Physiol 290, R509 R513.
15. Kok P, Roelfsema F, Frolich M, van Pelt J, Stokkel MP, Meinders AE & Pijl H (2006). Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab 291, E1038 E1043.
16. Landsberg L (2001). Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 19, 523 528.
17. Li SJ, Varga K, Archer P, Hruby VJ, Sharma SD, Kesterson RA, Cone RD & Kunos G (1996). Melanocortin antagonists define two distinct pathways of cardiovascular control by α- and γ-melanocyte-stimulating hormones. J Neurosci 16, 5182 5188.
18. Luo S, Liang Y & Cincotta AH (1999). Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose- intolerant state in hamsters. Neuroendocrinology 69, 160 166.
19. Mannelli M, Delitala G, De Feo ML, Maggi M, Cuomo S, Piazzini M, Guazzelli R & Serio M (1984). Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J Clin Endocrinol Metab 59, 74 78.
20. Mayan H, Ling KT, Lee EY, Wiedemann E, Kalinyak JE & Humphreys MH (1996). Dietary sodium intake modulates pituitary proopiomelanocortin mRNA abundance. Hypertension 28, 244 249.
21. Mayan H, Ni XP, Almog S & Humphreys MH (2003). Suppression of γ-melanocyte-stimulating hormone secretion is accompanied by salt-sensitive hypertension in the rat. Hypertension 42, 962 967.
22. Meneton P, Jeunemaitre X, de Wardener HE & MacGregor GA (2005). Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 85, 679 715.
23. Muntzel MS, Crespo R, Joseph T & Onwumere O (2007). Dietary salt loading exacerbates the increase in sympathetic nerve activity caused by intravenous insulin infusion in rats. Metabolism 56, 373 379.
24. Nagahama S, Chen YF & Oparil S (1984). Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. J Pharmacol Exp Ther 228, 370 375.
25. Nagahama S, Chen YF & Oparil S (1985). Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat. Am J Physiol Heart Circ Physiol 249, H64 H70.
26. Ni XP & Humphreys MH (2007). Prevention of salt-induced hypertension by an analog of γ-melanocyte-stimulating hormone in the rat. Am J Hypertens 20, 862 865.
27. Ni XP & Humphreys MH (2008). Abnormal glucose metabolism in hypertensive mice with genetically interrupted γ-melanocyte stimulating hormone signaling fed a high-sodium diet. Am J Hypertens 21, 1284 1287.
28. Ni XP, Kesterson RA, Sharma SD, Hruby VJ, Cone RD, Wiedemann E & Humphreys MH (1998). Prevention of reflex natriuresis after acute unilateral nephrectomy by melanocortin receptor antagonists. Am J Physiol Regul Integr Comp Physiol 274, R931 R938.
29. Ni XP, Pearce D, Butler AA, Cone RD & Humphreys MH (2003). Genetic disruption of γ-melanocyte-stimulating hormone signaling leads to salt-sensitive hypertension in the mouse. J Clin Invest 111, 1251 1258.
30. Ogihara T, Asano T & Fujita T (2003). Contribution of salt intake to insulin resistance associated with hypertension. Life Sci 73, 509 523.
31. Oguro M, Takeda K, Itoh H, Takesako T, Tanaka M, Takenaka K et al 1992). Role of sympathetic nerve inhibition in the vasodepressor effect of bromocriptine in normotensive and hypertensive rats. Jpn Circ J 56, 943 949.
32. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH & DeFronzo RA (2000). Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23, 1154 1161.
33. Racz K, Kuchel O & Buu NT (1986). Bromocriptine decreases blood pressure of spontaneously hypertensive rats without affecting the adrenomedullary synthesis of catecholamines. J Cardiovasc Pharmacol 8, 676 680.
34. Reaven GM, Lithell H & Landsberg L (1996). Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334, 374 381.
35. Sowers JR (1981). Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension. J Clin Endocrinol Metab 53, 1133 1137.
36. Stier CT Jr., Cowden EA & Allison ME (1982). Effects of bromocriptine on single nephron and whole-kidney function in rats. J Pharmacol Exp Ther 220, 366 370.
37. Van Den Buuse M & Lambrechts AC (1989). Bromocriptine-induced decrease in blood pressure in conscious spontaneously hypertensive rats: evidence for a peripheral site of action. J Pharm Pharmacol 41, 644 646.
38. Weinberger MH (1996). Salt sensitivity of blood pressure in humans. Hypertension 27, 481 490.